3-D Matrix Ltd. engages in the research, development, manufacture, and sale of medical products. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 114 full-time employees. The company went IPO on 2011-10-24. Its Medical Products Business consists of the development and sales of medical products. Based on self-assembling peptide technology, it conducts research and development of medical devices and pharmaceuticals in the surgical, tissue regeneration, and drug delivery system (DDS) fields. Major development pipelines include absorbable topical hemostatic agents, mucosal elevation agents, post-bleeding prevention agents, next-generation hemostatic agents, and adhesion prevention agents in the surgical field, wound healing agents and alveolar bone reconstruction agents in the tissue regeneration field, and DDS for nucleic acid drugs in the DDS field.
DMTRF stock price ended at $2.5 on 月曜日, after rising 0.00%
On the latest trading day Jul 20, 2026, the stock price of DMTRF rose by 0.00%, climbing from $2.50 to $2.50. Throughout the session, the stock experienced a volatility of 0.00%, with prices fluctuating between a daily low of $2.50 and a high of $2.50. Alongside this price increase, trading volume also rose by 1.5K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 200 shares were traded, amounting to a market value of approximately $319.9M.